Top in GI: AI-assisted colonoscopy, FDA denial of budesonide for eosinophilic esophagitis
Click Here to Manage Email Alerts
A new study showed that artificial intelligence-assisted colonoscopy increased the adenoma detection rate in patients at average risk for colorectal cancer. It was the top story in gastroenterology last week.
In the second top story, Ikuo Hirano, MD, a professor of medicine at Northwestern University Feinberg School of Medicine, discussed the FDA’s response to Takeda Pharmaceutical Company’s new drug application for budensonide oral suspension (BOS) as a treatment for eosinophilic esophagitis. The agency denied the approval of BOS in December, recommending additional clinical research on the treatment.
Read these and more top stories in gastroenterology below:
AI-assisted colonoscopy increases adenoma detection rate
Artificial intelligence-assisted colonoscopy reduced the colorectal neoplasia miss rate by nearly twofold compared with colonoscopy alone, according to research published in Gastroenterology. Read more.
Budesonide for EoE: Why the FDA denial is so hard to swallow
In December 2021, the FDA issued a complete response letter to Takeda Pharmaceutical Company for its new drug application for BOS for the treatment of eosinophilic esophagitis in adolescents and adults. Read more.
Heavy alcohol use increases liver impairment, risk for HCC in hepatitis-induced cirrhosis
Among patients with hepatitis-induced cirrhosis, heavy alcohol consumption increased liver function impairment and hepatocellular carcinoma prevalence, according to research. Read more.
NAFLD linked to lower early-stage detection, poorer survival in patients with HCC
Nonalcoholic fatty liver disease correlated with lower hepatocellular carcinoma surveillance receipt, early-stage detection and poorer survival compared with other HCC etiologies, according to research. Read more.
Is FDA approval in sight for emerging EoE therapies?
Over the years, there have been many advances in the pathologic understanding of eosinophilic esophagitis, but FDA-approved treatment options have lagged. Read more.